Management of toxicities of immune checkpoint inhibitors
Top Cited Papers
- 5 February 2016
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 44, 51-60
- https://doi.org/10.1016/j.ctrv.2016.02.001
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialThe Lancet Oncology, 2013
- The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysisJournal of the American Academy of Dermatology, 2013
- Multifocal radiculoneuropathy during ipilimumab treatment of melanomaMuscle & Nerve, 2013
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete RemissionJournal of Clinical Oncology, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007